Oncolines B.V.

Oncolines is a precision medicine services company based in Oss, The Netherlands, specializing in oncology and cancer immunotherapy. It is part of Symeres B.V. located in Nijmegen, The Netherlands. The company's primary focus is to accelerate the identification of improved and novel therapies tailored to specific patient populations. The client base of Oncolines comprises clinical and preclinical biopharmaceutical companies seeking to differentiate their drug candidates. The company offers a range of services including comprehensive compound characterization, activity determination, selectivity assessments, and mechanism of action elucidation. Notably, Oncolines presents results in a unique interactive reporting format, enhancing the interpretability and expediting the decision-making process. One of the key offerings by Oncolines is Oncolines Profiling, which involves parallel dose-response testing of compounds on a large panel of genetically characterized human cancer cell lines. This helps in identifying drug response biomarkers for patient population selection in clinical trials by analyzing the correlation and mutation status of over 100 cancer genes. Additionally, the company provides SynergyFinder, a service dedicated to profiling combinations of drugs to uncover new synergistic drug combinations, along with gene and protein expression analysis, DNA and RNA sequencing, and flow cytometry to investigate the mechanism of action of drug candidates. Moreover, with ResidenceTimer, Oncolines determines the binding kinetics of compound-target interactions, leveraging a repository of more than 100 kinase assays. It is important to highlight QuickScout, which involves kinase inhibitor profiling in enzyme activity assays at Carna Biosciences, Inc., with a representation in Europe and Israel. This provides access to 326 wild-type and mutant kinases for profiling (% effect and IC50). Oncolines, established in 2021, operates within the Health Care industry, and its headquarters are located in the Netherlands. As of now, there is no public information available regarding the company's recent investment activities or involved investors.